| __timestamp | BeiGene, Ltd. | Pharming Group N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 4042025 |
| Thursday, January 1, 2015 | 7311000 | 5279557 |
| Friday, January 1, 2016 | 20097000 | 8073913 |
| Sunday, January 1, 2017 | 62602000 | 44864073 |
| Monday, January 1, 2018 | 195385000 | 53488904 |
| Tuesday, January 1, 2019 | 388249000 | 65896361 |
| Wednesday, January 1, 2020 | 600176000 | 69968267 |
| Friday, January 1, 2021 | 990123000 | 92047281 |
| Saturday, January 1, 2022 | 1277852000 | 131819000 |
| Sunday, January 1, 2023 | 1504501000 | 87501000 |
Unleashing insights
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for operational efficiency. Over the past decade, BeiGene, Ltd. and Pharming Group N.V. have showcased contrasting trajectories in their SG&A expenditures.
From 2014 to 2023, BeiGene's SG&A expenses skyrocketed by over 21,500%, reflecting its aggressive expansion and investment in global operations. This surge underscores BeiGene's commitment to scaling its presence in the oncology sector, despite the high costs associated with such growth.
In contrast, Pharming Group's SG&A expenses grew by approximately 2,100% during the same period. This more measured increase highlights a strategic approach, focusing on sustainable growth and cost management.
As these companies continue to evolve, their SG&A strategies will remain pivotal in shaping their competitive edge in the biopharma landscape.
Operational Costs Compared: SG&A Analysis of Takeda Pharmaceutical Company Limited and Pharming Group N.V.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Summit Therapeutics Inc.
Comparing SG&A Expenses: BeiGene, Ltd. vs ADMA Biologics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Mesoblast Limited
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Pharming Group N.V.
Pharming Group N.V. and Madrigal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Pharming Group N.V. and Alpine Immune Sciences, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Pharming Group N.V. vs TG Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Pharming Group N.V. vs ADMA Biologics, Inc.
Pharming Group N.V. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?